# Apidra

NDC: 0088-2500
Generic name: insulin glulisine
Labeler / Manufacturer: sanofi-aventis U.S. LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: INTRAVENOUS, SUBCUTANEOUS
Marketing started: 20090224

FDA application: BLA021629

## Active ingredients

- INSULIN GLULISINE: 100 [iU]/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0088-2500"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0088-2500
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7af6a7a-8046-4fb4-9979-4ec4230b23aa